Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis
Staphylococcus aureus is a ubiquitous human commensal pathogen. It is commonly isolated in cystic fibrosis (CF) patients and is considered one of the main causes of the recurrent acute pulmonary infections and progressive decline in lung function that characterize this inherited life-threatening mul...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00849/full |
| _version_ | 1819054350088011776 |
|---|---|
| author | Susanna Esposito Guido Pennoni Valeria Mencarini Nicola Palladino Laura Peccini Nicola Principi |
| author_facet | Susanna Esposito Guido Pennoni Valeria Mencarini Nicola Palladino Laura Peccini Nicola Principi |
| author_sort | Susanna Esposito |
| collection | DOAJ |
| description | Staphylococcus aureus is a ubiquitous human commensal pathogen. It is commonly isolated in cystic fibrosis (CF) patients and is considered one of the main causes of the recurrent acute pulmonary infections and progressive decline in lung function that characterize this inherited life-threatening multisystem disorder. However, the true role of S. aureus in CF patients is not completely understood. The main aim of this narrative review is to discuss the present knowledge of the role of S. aureus in CF patients. Literature review showed that despite the fact that the availability and use of drugs effective against S. aureus have coincided with a significant improvement in the prognosis of lung disease in CF patients, clearly evidencing the importance of S. aureus therapy, how to use old and new drugs to obtain the maximal effectiveness has not been precisely defined. The most important problem remains that the high frequency with which S. aureus is carried in healthy subjects prevents the differentiation of simple colonization from infection. Moreover, although experts recommend antibiotic administration in CF patients with symptoms and in those with persistent detection of S. aureus, the best antibiotic approach has not been defined. All these problems are complicated by the evidence that the most effective antibiotic against methicillin-resistant S. aureus (MRSA) cannot be used in patients with CF with the same schedules used in patients without CF. Further studies are needed to solve these problems and to assure CF patients the highest level of care. |
| first_indexed | 2024-12-21T12:50:13Z |
| format | Article |
| id | doaj.art-0472a35cb46843f8b244f9a118c39754 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-21T12:50:13Z |
| publishDate | 2019-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-0472a35cb46843f8b244f9a118c397542022-12-21T19:03:31ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-08-011010.3389/fphar.2019.00849464820Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic FibrosisSusanna Esposito0Guido Pennoni1Valeria Mencarini2Nicola Palladino3Laura Peccini4Nicola Principi5Pediatric Clinic, Cystic Fibrosis Center of Umbria Region, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, ItalyPediatric Unit, Cystic Fibrosis Center of Umbria Region, Branca Hospital, Branca, ItalyPediatric Unit, Cystic Fibrosis Center of Umbria Region, Branca Hospital, Branca, ItalyPediatric Unit, Cystic Fibrosis Center of Umbria Region, Branca Hospital, Branca, ItalyPediatric Clinic, Cystic Fibrosis Center of Umbria Region, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, ItalyUniversità degli Studi di Milano, Milan, ItalyStaphylococcus aureus is a ubiquitous human commensal pathogen. It is commonly isolated in cystic fibrosis (CF) patients and is considered one of the main causes of the recurrent acute pulmonary infections and progressive decline in lung function that characterize this inherited life-threatening multisystem disorder. However, the true role of S. aureus in CF patients is not completely understood. The main aim of this narrative review is to discuss the present knowledge of the role of S. aureus in CF patients. Literature review showed that despite the fact that the availability and use of drugs effective against S. aureus have coincided with a significant improvement in the prognosis of lung disease in CF patients, clearly evidencing the importance of S. aureus therapy, how to use old and new drugs to obtain the maximal effectiveness has not been precisely defined. The most important problem remains that the high frequency with which S. aureus is carried in healthy subjects prevents the differentiation of simple colonization from infection. Moreover, although experts recommend antibiotic administration in CF patients with symptoms and in those with persistent detection of S. aureus, the best antibiotic approach has not been defined. All these problems are complicated by the evidence that the most effective antibiotic against methicillin-resistant S. aureus (MRSA) cannot be used in patients with CF with the same schedules used in patients without CF. Further studies are needed to solve these problems and to assure CF patients the highest level of care.https://www.frontiersin.org/article/10.3389/fphar.2019.00849/fullantibioticscystic fibrosisMRSApulmonary exacerbationStaphylococcus aureus |
| spellingShingle | Susanna Esposito Guido Pennoni Valeria Mencarini Nicola Palladino Laura Peccini Nicola Principi Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis Frontiers in Pharmacology antibiotics cystic fibrosis MRSA pulmonary exacerbation Staphylococcus aureus |
| title | Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis |
| title_full | Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis |
| title_fullStr | Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis |
| title_full_unstemmed | Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis |
| title_short | Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis |
| title_sort | antimicrobial treatment of staphylococcus aureus in patients with cystic fibrosis |
| topic | antibiotics cystic fibrosis MRSA pulmonary exacerbation Staphylococcus aureus |
| url | https://www.frontiersin.org/article/10.3389/fphar.2019.00849/full |
| work_keys_str_mv | AT susannaesposito antimicrobialtreatmentofstaphylococcusaureusinpatientswithcysticfibrosis AT guidopennoni antimicrobialtreatmentofstaphylococcusaureusinpatientswithcysticfibrosis AT valeriamencarini antimicrobialtreatmentofstaphylococcusaureusinpatientswithcysticfibrosis AT nicolapalladino antimicrobialtreatmentofstaphylococcusaureusinpatientswithcysticfibrosis AT laurapeccini antimicrobialtreatmentofstaphylococcusaureusinpatientswithcysticfibrosis AT nicolaprincipi antimicrobialtreatmentofstaphylococcusaureusinpatientswithcysticfibrosis |